Get our July/August issue now

available for iOS, Android and web


FDA OK for Taro's psoriasis spray

World News | April 15, 2013


Selina McKee

FDA OK for Taro's psoriasis spray

US regulators have issued a green light for Taro Pharmaceutical Industries' corticosteroid psoriasis spray.

The group said that the US Food and Drug Administration has approved its application to market Topicort (desoximetasone) Topical Spray for the treatment of plaque psoriasis in patients 18 years of age or older.

Psoriasis is the most prevalent autoimmune disease in the US, affecting as many as 7.5 million - or 2.2% - of the population.  

Taro, citing "industry sources", noted that the corticosteroid spray market in the US is worth around $100 million a year.

Click here to order a reprint of this news story.

Tags


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

JobSearch


Head-to-Head Video

 

Website Search


Search News Search Magazine